Free Trial
NASDAQ:CHRN

ChronoScale Corporation Common Stock Q3 2025 Earnings Report

ChronoScale Corporation Common Stock logo
$11.95 +0.15 (+1.27%)
Closing price 05/4/2026 07:57 PM Eastern
Extended Trading
$11.95 0.00 (0.00%)
As of 05/4/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ChronoScale Corporation Common Stock EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.99
Beat/Miss
Beat by +$0.45
One Year Ago EPS
N/A

ChronoScale Corporation Common Stock Revenue Results

Actual Revenue
$4.23 million
Expected Revenue
$4.16 million
Beat/Miss
Beat by +$71.00 thousand
YoY Revenue Growth
N/A

ChronoScale Corporation Common Stock Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, October 28, 2025
Conference Call Time
4:00PM ET

ChronoScale Corporation Common Stock Earnings Headlines

Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
Ekso Bionics Holdings, Inc.
See More ChronoScale Corporation Common Stock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ChronoScale Corporation Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ChronoScale Corporation Common Stock and other key companies, straight to your email.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions. These devices are utilized in hospitals and rehabilitation centers across North America and Europe, enabling physical therapists to deliver overground gait training with customizable robotic support and integrated performance tracking.

On the industrial side, EksoWorks exoskeletons—including the EksoVest and EksoZeroG—help reduce workplace fatigue and lower the risk of musculoskeletal injuries in manufacturing, warehousing and automotive assembly. By offloading weight and supporting the arms or torso, these wearable solutions improve ergonomics, enhance worker safety and boost productivity in environments that involve repetitive overhead or lifting tasks.

Ekso Bionics serves a global customer base spanning the United States, Europe and Asia. The company’s leadership team, led by Chief Executive Officer Paul R. Sandner, brings together expertise in robotics, biomechanics and healthcare to drive ongoing innovation and expand market adoption of wearable robotics technologies.

View ChronoScale Corporation Common Stock Profile